Lafolie P, Hayder S, Björk O, Peterson C
Department of Clinical Pharmacology, Karolinska Hospital, Stockholm, Sweden.
Eur J Clin Pharmacol. 1991;40(6):599-601. doi: 10.1007/BF00279977.
Intraindividual variation in 6-mercaptopurine (6-MP) kinetics has been little studied. It has now been examined in 18 children with acute lymphoblastic leukaemia (ALL). On 2 to 4 occasions in each patient drug concentrations in plasma and red cells were followed for 4 h after administration by means of HPLC. The mean individual coefficient of variation (C.V.) in AUC was 57.9% and it was not related to dose or concentration. The variation was the same in plasma and in red cells. It is concluded that regular monitoring of 6-mercaptopurine concentration would identify periods when a patient deviates strongly from the mean range. Both undertreatment and concentration-dependent toxicity could then be corrected.
6-巯基嘌呤（6-MP）动力学的个体内差异鲜有研究。现已对18例急性淋巴细胞白血病（ALL）患儿进行了此项研究。在每位患者2至4个不同时间点，给药后通过高效液相色谱法（HPLC）对血浆和红细胞中的药物浓度进行4小时监测。AUC的个体平均变异系数（C.V.）为57.9%，且与剂量或浓度无关。血浆和红细胞中的变异情况相同。得出的结论是，定期监测6-巯基嘌呤浓度可识别出患者明显偏离平均范围的时期。进而可以纠正治疗不足和浓度依赖性毒性。
